BCL2 and lymphoma: Both in WHO-HAEM5 and the ICC, however, a fundamental change is that this entity comprises only cases with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2), with or without additional BCL6 breaks, so that aggressive lymphomas with dual rearrangements of MYC and BCL6 (without BCL2) are excluded.